Report Contents
Market Overview
The global Companion Diagnostics Devices market is transitioning from an emerging niche to a core pillar of precision oncology and targeted therapies, with revenue estimated at about USD 7.90 Billion in 2025. Fueled by regulatory support for biomarker-driven drug approvals, the market is projected to grow at a robust 12.30% CAGR from 2026 to 2032, reaching approximately USD 17.90 Billion by 2032 as companion diagnostics become embedded across clinical pathways and pharmaceutical pipelines.
Strategic success in this market hinges on several imperatives: scalable assay platforms that can handle rising test volumes, localization of test menus and reimbursement strategies to fit diverse regional healthcare systems, and deep technological integration with next-generation sequencing, digital pathology, and bioinformatics. Converging trends such as personalized immuno-oncology, decentralized testing models, and real-world evidence generation are expanding the market’s scope beyond traditional laboratory environments and redefining competitive dynamics. Within this context, the report positions itself as an essential strategic tool, offering forward-looking analysis of key investment decisions, partnership structures, and disruptive innovations that will shape profitable market entry and long-term leadership.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Companion Diagnostics Devices Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Companion Diagnostics Devices Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Polymerase Chain Reaction Based Companion Diagnostics Devices:
Polymerase chain reaction based companion diagnostics devices currently hold a central position in the market because they are deeply embedded in oncology workflows and have long-standing regulatory acceptance. These platforms are widely used to detect specific gene mutations, such as EGFR or KRAS, and typically deliver analytical sensitivity down to low single-digit copy numbers per reaction, making them suitable for early-stage tumor profiling. Their broad installed base in hospital laboratories and reference centers reinforces their dominance, particularly in mature healthcare systems.
The key competitive advantage of these devices lies in their combination of high analytical sensitivity and relatively low cost per test, which can reduce per-sample diagnostic expenses by an estimated 20.00% to 40.00% compared with more complex sequencing approaches. Standardized assay kits and automation-compatible instruments allow throughput of several hundred samples per day in high-volume labs, supporting rapid turnaround times that are critical for treatment selection. Ongoing growth is fueled by the steady expansion of targeted therapies that require single or limited biomarker confirmation, as well as favorable reimbursement frameworks that prioritize cost-effective, clinically validated assays.
-
Next Generation Sequencing Based Companion Diagnostics Devices:
Next generation sequencing based companion diagnostics devices have rapidly moved into a strategic growth position because they enable multiplex genomic profiling within a single run. These devices can interrogate dozens to hundreds of clinically actionable genes simultaneously, providing a comprehensive view of tumor mutational status for complex cancers such as non-small cell lung cancer and ovarian cancer. Their role is particularly strong in tertiary oncology centers and precision medicine networks that require broad biomarker coverage for clinical decision support.
The competitive advantage of next generation sequencing platforms stems from their high throughput and data richness, with modern systems capable of processing several thousand samples per month at a cost per gene that can be 60.00% to 80.00% lower than running multiple single-analyte tests. This scalability supports panel-based companion diagnostics that align with the growing number of multi-target therapies and clinical trial protocols. Market growth is catalyzed by regulatory acceptance of multi-gene panels, declining sequencing costs, and the rise of national precision oncology initiatives that embed next generation sequencing into standard-of-care treatment algorithms.
-
Immunohistochemistry Based Companion Diagnostics Devices:
Immunohistochemistry based companion diagnostics devices hold a well-established position because they are integral to anatomic pathology workflows and require relatively modest infrastructure. These devices are extensively used to assess protein expression markers such as PD-L1, HER2, and hormone receptors, which are pivotal in selecting immunotherapies and targeted biologics. Their adoption is particularly strong in community hospitals and regional cancer centers where pathologists rely on slide-based evaluation.
The primary competitive advantage of immunohistochemistry lies in its direct visualization of biomarker expression within tissue architecture, offering clinically intuitive results with turnaround times often under 24.00 hours. Automated staining platforms can process dozens to more than 100.00 slides per run, and reagent costs per test remain comparatively low, supporting widespread use even in cost-sensitive environments. Growth is currently driven by the expansion of immuno-oncology indications that rely on protein expression thresholds, as well as continuous improvements in automated staining precision and digital pathology integration that enhance reproducibility and workflow efficiency.
-
In Situ Hybridization Based Companion Diagnostics Devices:
In situ hybridization based companion diagnostics devices occupy a specialized yet critical niche, particularly for detecting gene amplifications and chromosomal rearrangements such as HER2 amplification or ALK and ROS1 rearrangements. These assays are embedded in oncology guidelines for specific tumor types, which secures a stable baseline demand. Their use is most concentrated in reference pathology laboratories and academic medical centers equipped with advanced microscopy and image analysis capabilities.
The distinctive competitive advantage of in situ hybridization is its ability to localize nucleic acid signals directly within tissue sections, achieving high specificity while preserving morphological context. Although throughput is typically lower than polymerase chain reaction or next generation sequencing, modern automated systems can manage several dozen slides per batch and reduce manual labor time by an estimated 30.00% to 50.00%. Growth is fueled by guideline-driven testing requirements, regulatory approvals that specify in situ hybridization as a companion diagnostic method, and technological advances in automation and digital imaging that improve consistency and reduce interpretation variability.
-
Liquid Biopsy Based Companion Diagnostics Devices:
Liquid biopsy based companion diagnostics devices represent one of the fastest-growing segments due to their non-invasive sampling and suitability for longitudinal monitoring. These platforms analyze circulating tumor DNA, circulating tumor cells, or other blood-based biomarkers to guide therapy selection, particularly when tissue biopsies are difficult or unsafe. Their role is increasing in metastatic cancer management, minimal residual disease assessment, and real-time resistance mutation tracking.
The competitive advantage of liquid biopsy devices lies in their ability to provide high clinical utility with minimal patient burden, as a simple blood draw can replace or defer invasive tissue procedures in a significant portion of cases. Advanced technologies have improved sensitivity to detect mutant allele fractions below 0.50%, which supports early detection of emerging resistance and enables more agile treatment adjustments. Market expansion is driven by technological refinements that enhance analytical sensitivity, expanding regulatory clearances for blood-based companion diagnostics, and payer recognition of the cost savings associated with fewer invasive procedures and optimized therapy sequencing.
-
Mass Spectrometry Based Companion Diagnostics Devices:
Mass spectrometry based companion diagnostics devices currently serve a more focused but strategically important role in quantifying proteins, metabolites, and certain small-molecule biomarkers with high precision. These systems are particularly relevant in situations where absolute quantification and high specificity are required, such as therapeutic drug monitoring for targeted agents or precise measurement of predictive protein markers. Adoption is strongest in advanced clinical laboratories and specialized centers with expertise in high-end analytical instrumentation.
The competitive advantage of mass spectrometry platforms stems from their exceptional analytical specificity and reproducibility, with coefficient of variation levels often below 10.00% in well-validated assays and dynamic ranges that exceed those of many immunoassay-based methods. Once established, multiplexed mass spectrometry methods can lower per-analyte costs by analyzing multiple targets in a single run while maintaining high throughput sufficient for routine clinical workflows. Growth is catalyzed by increasing demand for quantitative proteomics in oncology, the need for robust drug level monitoring in precision dosing strategies, and ongoing instrument innovations that simplify operation and integration into regulated clinical environments.
Market By Region
The global Companion Diagnostics Devices market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents a core revenue engine for the global Companion Diagnostics Devices market, underpinned by high oncology and immunology testing volumes and a dense network of reference laboratories. The United States and Canada drive the region’s leadership, supported by advanced hospital systems, robust reimbursement frameworks and strong collaborations between diagnostic manufacturers and biopharmaceutical companies for co-developed therapies.
The region is estimated to contribute a substantial portion of the global market, acting as a mature but still expanding base that stabilizes worldwide revenue as the total market grows from USD 7,90 Billion in 2025 to USD 17,90 Billion by 2032 at a 12,30% CAGR. Key untapped potential lies in extending companion diagnostic adoption beyond major academic centers into community oncology clinics, smaller integrated delivery networks and remote areas where access to molecular pathology, next-generation sequencing and biomarker testing remains limited.
-
Europe:
Europe holds strategic significance in the Companion Diagnostics Devices industry due to its stringent regulatory environment, strong clinical research infrastructure and high adoption of precision medicine in oncology and rare diseases. Germany, the United Kingdom, France and the Nordics act as primary market drivers, supported by national cancer plans, centralized laboratory networks and active health technology assessments that increasingly recognize biomarker-guided therapy.
The region accounts for a meaningful share of global revenues, characterized by a relatively mature yet heterogeneous market in which reimbursement, regulatory timelines and laboratory consolidation differ by country. Untapped potential exists in Southern and Eastern European markets, where companion diagnostic penetration in public hospitals and regional laboratories is still emerging. Addressing funding gaps, harmonizing quality standards for molecular testing and expanding digital pathology infrastructure are critical to unlocking further growth and capturing a larger portion of the expanding global market value.
-
Asia-Pacific:
The broader Asia-Pacific region serves as one of the fastest-growing segments of the Companion Diagnostics Devices landscape, driven by rising cancer incidence, expanding middle-class populations and rapid investment in molecular diagnostic laboratories. Key growth engines include India, Australia, Singapore and emerging Southeast Asian economies, which are strengthening their precision oncology ecosystems and partnering with global diagnostic manufacturers for localized test development.
Asia-Pacific contributes an increasing share of global market expansion, acting as a high-growth complement to the mature markets of North America and Europe as worldwide revenues move toward USD 8,90 Billion in 2026 and beyond. Despite strong momentum, large rural and semi-urban populations remain underserved, with limited access to PCR-based companion assays, NGS platforms and high-quality sample logistics. Overcoming shortages of trained molecular pathologists, fragmented reimbursement structures and infrastructure constraints will be essential to capture the region’s significant latent demand.
-
Japan:
Japan holds unique strategic importance as a standalone market in the Companion Diagnostics Devices industry because of its rapid uptake of targeted oncology drugs and its sophisticated hospital-based laboratory networks. The country’s health insurance system and centralized evaluation of diagnostics and therapeutics support early adoption of approved companion tests, particularly for lung, breast and gastrointestinal cancers.
Japan commands a notable share within the Asia-focused segment of the global market and provides a stable, innovation-oriented revenue stream for manufacturers seeking premium pricing for advanced assays. However, opportunities remain to expand beyond major university hospitals into regional centers and community cancer networks, where access to complex NGS-based companion diagnostics can lag. Streamlining regulatory review times, improving interoperability of clinical data systems and enhancing education for clinicians on biomarker-driven treatment algorithms will help unlock additional growth in this technologically advanced yet unevenly penetrated market.
-
Korea:
Korea is an increasingly influential player in the Companion Diagnostics Devices market, leveraging strong national cancer screening programs, high broadband connectivity and well-equipped tertiary hospitals. The country’s leading medical centers in Seoul and other metropolitan areas act as hubs for biomarker-driven clinical trials and early implementation of companion assays linked to targeted therapies and immuno-oncology products.
While Korea’s absolute market size is smaller than that of regional giants, it contributes disproportionately to innovation and early adoption within Asia-Pacific, supporting overall global growth through fast technology diffusion. Significant potential lies in broadening companion diagnostic utilization beyond flagship hospitals to second-tier regional institutions, which still rely heavily on conventional histopathology. Addressing reimbursement constraints for advanced molecular tests, bolstering local manufacturing capabilities and enhancing physician awareness of guideline-recommended companion diagnostics will be critical to fully realizing the country’s high-growth trajectory.
-
China:
China represents one of the most strategically critical and rapidly expanding markets for Companion Diagnostics Devices, fueled by a large oncology patient base, government-backed healthcare reforms and aggressive investment in domestic in vitro diagnostics manufacturers. Major metropolitan areas such as Beijing, Shanghai, Guangzhou and Shenzhen anchor demand through high-volume cancer centers and reference laboratories that increasingly deploy NGS panels and immunohistochemistry-based companion assays.
The country is estimated to account for a growing fraction of global market growth, transitioning from a primarily volume-driven diagnostic ecosystem to one centered on precision therapeutics and biomarker stratification. Despite strong progress, vast provincial and rural regions remain underpenetrated, with limited access to complex companion tests and inconsistent quality assurance in molecular laboratories. Expanding reimbursement for companion diagnostics, improving regulatory clarity for locally developed assays and scaling logistics for biospecimen handling are key levers for unlocking the full potential of this high-impact market in the context of a global industry growing at 12,30% annually.
-
USA:
The USA constitutes the single largest national market for Companion Diagnostics Devices, driven by high healthcare expenditure, extensive oncology drug pipelines and close integration between diagnostic developers and pharmaceutical sponsors. Major academic medical centers, national reference laboratories and integrated delivery networks anchor demand for FDA-approved companion assays, particularly in non-small cell lung cancer, breast cancer, colorectal cancer and hematologic malignancies.
The country contributes a dominant share of global revenues and serves as the primary launchpad for novel companion diagnostic platforms before they diffuse internationally, thereby shaping adoption patterns across other regions. Nonetheless, substantial opportunity remains in improving access in community oncology practices, safety-net hospitals and rural health systems, where advanced molecular profiling is still underutilized. Addressing reimbursement variability among private payers, streamlining test ordering workflows within electronic health records and enhancing patient enrollment in biomarker-driven clinical trials will be essential to deepen market penetration and sustain growth as global revenues rise from USD 7,90 Billion toward 17,90 Billion over the forecast horizon.
Market By Company
The Companion Diagnostics Devices market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Roche Diagnostics:
Roche Diagnostics holds a pivotal role in the companion diagnostics devices market due to its deep integration of pharma and diagnostics, particularly in oncology and immunotherapy. The company’s long-standing presence in in vitro diagnostics and its extensive installed base of analyzers in hospitals and reference laboratories make it a default partner for many targeted therapies. Its co-development programs with pharmaceutical manufacturers position Roche as a reference player for regulatory-cleared companion diagnostic assays.
In 2025, Roche Diagnostics is estimated to generate companion diagnostics-related revenue of USD 1.80 billion, translating into a market share of approximately 22.80%. These figures indicate a clear leadership position in a global market valued at USD 7.90 billion in 2025, reflecting both scale and strong pull-through from its assay menu on centralized and molecular platforms. The company’s revenue concentration in oncology biomarkers demonstrates its ability to capture value where reimbursement and clinical demand are strongest.
Roche’s strategic advantage stems from its integrated pharma–diagnostics model, strong regulatory track record, and broad biomarker portfolio spanning EGFR, HER2, PD-L1, and multiple next-generation sequencing panels. The company differentiates itself through end-to-end solutions that combine instruments, reagents, software, and clinical decision support. Compared with peers, Roche’s close alignment with major oncology drug launches and its global distribution network provide a sustained edge in companion test adoption, especially in Europe and high-value hospital systems worldwide.
-
Agilent Technologies:
Agilent Technologies plays a prominent role in the companion diagnostics devices space, particularly in tissue-based assays and pathology workflows. The company is a major supplier of immunohistochemistry platforms and reagents used to stratify patients for targeted therapies, making it a key partner for oncology drug developers focused on solid tumors. Its solutions are deeply embedded in pathology labs, which are essential gateways for companion diagnostics adoption.
For 2025, Agilent’s companion diagnostics-related revenue is estimated at USD 0.55 billion, corresponding to a market share of around 6.90%. This position reflects a strong but more focused footprint compared with the largest integrated diagnostics houses. The company’s share underscores its competitiveness in niche but clinically critical segments such as PD-L1 testing and advanced tissue biomarkers used in immuno-oncology and targeted therapies.
Agilent’s strategic strengths lie in its expertise in pathology workflows, high-quality antibodies, and co-development partnerships with biopharma for assay development tied to specific drug labels. Its open collaboration model and regulatory experience help differentiate it from broader diversified diagnostics players. While it may not match the scale of the largest firms, Agilent competes effectively through high assay quality, reliable instrumentation, and strong relationships with pathologists and oncologists who rely on accurate biomarker assessment for treatment decisions.
-
Thermo Fisher Scientific:
Thermo Fisher Scientific is a critical enabler of the companion diagnostics devices market, particularly through its next-generation sequencing platforms and PCR-based systems. The company’s technologies are widely used in clinical and translational research labs, and its regulatory-cleared NGS platforms are increasingly adopted for multiplexed companion diagnostic panels in oncology. Thermo Fisher’s broad portfolio, spanning instruments, reagents, and informatics, gives it a comprehensive presence across the clinical genomics value chain.
In 2025, Thermo Fisher’s revenue attributable to companion diagnostics devices is estimated at USD 0.95 billion, which equates to a market share of about 12.00%. These figures reflect its strong penetration into molecular laboratories that run NGS-based oncology panels and targeted PCR assays linked to approved therapies. The company’s scale and recurring consumables revenue demonstrate a robust competitive position and the ability to support high-throughput testing as precision oncology adoption accelerates.
Thermo Fisher’s competitive differentiation arises from its deep technology stack, strong R&D, and broad regulatory experience across multiple geographies. It offers integrated solutions from sample preparation and sequencing to bioinformatics pipelines and reporting, which simplifies implementation for clinical labs. Compared with more narrowly focused competitors, Thermo Fisher’s scale and diversified life science portfolio enable sustained investment in new biomarkers, higher sensitivity platforms, and automation, positioning it as a partner of choice for complex companion diagnostic development programs.
-
Abbott Laboratories:
Abbott Laboratories contributes significantly to the companion diagnostics devices market through its molecular diagnostics and immunoassay platforms installed across hospitals and centralized laboratories. The company’s systems are widely used for infectious disease testing and are increasingly adapted for oncology and genetic assays that can serve as companion diagnostics when linked to targeted therapies. Abbott’s strong presence in core lab environments supports integration of companion testing into routine clinical workflows.
For 2025, Abbott’s companion diagnostics-related revenue is estimated at USD 0.60 billion, corresponding to a market share of roughly 7.60%. This performance illustrates a solid second-tier leadership position, leveraging a large installed base to drive incremental adoption of companion tests. The revenue level indicates meaningful participation but also suggests room for expansion as Abbott broadens its oncology and pharmacogenomic assay menu.
Abbott’s strategic advantages include high-throughput automation, robust assay reliability, and long-standing relationships with hospital laboratories and health systems. Its focus on workflow efficiency and integration into laboratory information systems gives it an edge in settings where turnaround time and operational efficiency are critical. Compared with more oncology-focused peers, Abbott differentiates through its ability to embed companion diagnostics into multi-analyte panels and existing platforms, allowing laboratories to scale testing without significant incremental capital investment.
-
Qiagen:
Qiagen is a core player in the companion diagnostics devices market, particularly in PCR-based and sample preparation technologies that underpin many molecular assays. The company has numerous co-development agreements with pharmaceutical manufacturers to create companion diagnostic kits for targeted therapies, especially in oncology and infectious diseases. Its regulatory-cleared kits are deployed in both centralized labs and decentralized settings using its cartridge-based systems.
In 2025, Qiagen’s revenue from companion diagnostics is estimated at USD 0.50 billion, yielding a market share of around 6.30%. These values highlight Qiagen’s strong presence in the regulated molecular diagnostics segment, with a focus on high-value companion tests that benefit from its robust sample-to-result workflows. Its scale indicates significant influence, yet leaves room to capture additional share as new biomarkers and therapy-linked assays enter the market.
Qiagen differentiates itself through its integrated sample preparation, PCR, and digital solutions, as well as its global installed base of modular platforms. Its ability to rapidly translate emerging biomarkers into standardized kits provides a competitive advantage relative to laboratories that rely on laboratory-developed tests. Compared with larger diversified diagnostics firms, Qiagen is more focused on molecular applications, allowing it to move quickly on new companion opportunities while maintaining strong regulatory and quality systems to support global commercialization.
-
Illumina:
Illumina plays a foundational role in the companion diagnostics devices market as the dominant provider of next-generation sequencing platforms. Many clinical laboratories and diagnostic companies build their oncology and hereditary disease panels on Illumina sequencers, which serve as the backbone for multi-gene companion diagnostics. Illumina’s ecosystem of reagents, instruments, and software supports both centralized reference labs and large oncology centers.
For 2025, Illumina’s companion diagnostics-related revenue is estimated at USD 0.70 billion, corresponding to a market share of about 8.90%. This performance reflects dominant influence at the platform level, even though a portion of companion diagnostic revenue flows through partner laboratories and test developers. The figures highlight Illumina’s critical role in enabling high-complexity genomic profiling that aligns with precision oncology guidelines.
Illumina’s strategic advantage is anchored in its sequencing accuracy, throughput scalability, and broad regulatory footprint in clinical applications. The company’s partnerships with diagnostic developers and pharmaceutical manufacturers allow it to embed its platforms in approved companion assays and clinical trial workflows. Compared with smaller sequencing competitors, Illumina benefits from a large installed base, robust bioinformatics, and continuous innovation in low-cost, high-throughput platforms, which reinforces its position at the center of NGS-based companion diagnostics.
-
Siemens Healthineers:
Siemens Healthineers is an important player in the companion diagnostics devices arena through its strong imaging and in vitro diagnostics presence. While traditionally recognized for imaging, the company’s immunoassay and molecular platforms provide opportunities to support companion diagnostics, particularly in oncology and cardiometabolic diseases where biomarker-guided therapy is expanding. Its integrated diagnostic imaging and lab ecosystems enable multimodal approaches to patient stratification.
In 2025, Siemens Healthineers’ revenue from companion diagnostics devices is estimated at USD 0.45 billion, representing a market share of approximately 5.70%. This indicates a substantial but not dominant position, reflecting a portfolio that is still ramping up in therapy-linked assays compared with its broader diagnostics and imaging businesses. Nevertheless, the scale demonstrates that Siemens is becoming an increasingly relevant contributor to precision medicine workflows.
Siemens Healthineers differentiates itself through its ability to integrate lab data, imaging findings, and digital health tools into cohesive diagnostic pathways. Its strengths in automation, enterprise IT integration, and global service infrastructure make it an attractive partner for health systems seeking scalable companion diagnostics deployment. Compared with pure-play molecular companies, Siemens leverages cross-modality clinical insights and strong hospital relationships, creating a competitive edge in complex chronic disease management where companion diagnostics and imaging must work together.
-
Danaher Corporation:
Danaher Corporation participates in the companion diagnostics devices market primarily through its diagnostics subsidiaries, which supply instrumentation, reagents, and workflow solutions to clinical laboratories. Its portfolio includes molecular and immunoassay platforms that support biomarker testing associated with targeted therapies. The company’s operating model emphasizes continuous improvement and disciplined integration of acquisitions, which strengthens its diagnostics capabilities over time.
For 2025, Danaher’s companion diagnostics-related revenue is estimated at USD 0.40 billion, leading to a market share of around 5.10%. These values reflect a meaningful but diversified presence, as Danaher’s diagnostics activity spans multiple segments, not solely companion testing. The revenue scale suggests solid competitiveness while leaving strategic headroom for further investment in precision medicine partnerships.
Danaher’s core advantages arise from its operational excellence, disciplined capital deployment, and breadth of diagnostic technologies. The company is well positioned to enhance companion diagnostic offerings through targeted acquisitions and innovation in automation, digital connectivity, and assay development. Compared with more narrowly focused firms, Danaher benefits from a strong balance sheet and portfolio flexibility, which allow it to rapidly scale promising companion diagnostics platforms and respond to emerging biomarker trends.
-
Myriad Genetics:
Myriad Genetics is a specialized player in the companion diagnostics devices market with a strong focus on oncology and women’s health genomics. The company pioneered several hereditary cancer tests and now offers tumor profiling and biomarker assays that inform therapy selection, particularly in breast, ovarian, and other solid tumors. Its tests are widely used by oncologists seeking genomic insights for treatment planning.
In 2025, Myriad Genetics’ revenue tied to companion diagnostics is estimated at USD 0.30 billion, corresponding to a market share of roughly 3.80%. These figures indicate a focused but influential role, particularly in specific cancer types and hereditary risk assessments that align closely with targeted therapies and PARP inhibitors. The company’s share underscores its strong brand recognition in oncology genetics despite the presence of larger diversified competitors.
Myriad’s strategic differentiation stems from its deep clinical genetics expertise, robust evidence base, and close relationships with oncologists and genetic counselors. It offers comprehensive support services, including reimbursement assistance and clinical interpretation, which enhance the practical utility of its companion diagnostics. Compared with larger diagnostics conglomerates, Myriad competes through specialization, high clinical utility, and strong integration into oncology care pathways, especially in North America.
-
BioMerieux:
BioMerieux is primarily known for its strengths in microbiology and infectious disease diagnostics, yet it also participates in the companion diagnostics devices market through biomarker assays that support targeted therapies and antimicrobial stewardship. The company’s platforms in immunoassay and molecular diagnostics are deployed in hospitals worldwide, creating a foundation for expanding therapy-linked testing.
For 2025, BioMerieux’s revenue from companion diagnostics devices is estimated at USD 0.25 billion, giving it a market share of about 3.20%. This position reflects a modest but strategic presence, with potential growth as more companion diagnostics emerge in infectious diseases and sepsis management. The revenue level signals that companion diagnostics are a growing, though not yet dominant, part of its overall portfolio.
BioMerieux’s competitive advantage lies in its established hospital footprint, expertise in infection diagnostics, and commitment to antimicrobial stewardship programs. As targeted anti-infective therapies and host-response biomarkers gain regulatory approval, the company is well positioned to develop and commercialize associated companion tests. Compared with oncology-centric competitors, BioMerieux differentiates itself by focusing on infectious disease pathways where rapid, precise diagnostics can guide therapy selection and improve outcomes in critical care settings.
-
Exact Sciences:
Exact Sciences is an innovation-driven participant in the companion diagnostics devices market, with a strong emphasis on oncology screening and minimal residual disease monitoring. While best known for stool-based colorectal cancer screening, the company increasingly offers blood-based and tissue-based genomic assays that can inform therapy selection and disease monitoring, aligning with companion diagnostic use cases in solid tumors.
In 2025, Exact Sciences’ revenue attributable to companion diagnostics is estimated at USD 0.35 billion, equal to a market share of around 4.40%. These values highlight the company’s rapid growth trajectory and expanding relevance in precision oncology, particularly as clinicians adopt molecular residual disease and prognostic assays alongside traditional companion diagnostics. The figures demonstrate that Exact Sciences is moving from a screening-focused business toward a broader precision medicine role.
Exact Sciences differentiates itself through its strong R&D pipeline, advanced liquid biopsy technologies, and focus on early detection and treatment stratification. Its assays often provide actionable genomic information using minimally invasive samples, which is increasingly attractive to oncologists and patients. Compared with larger incumbents, Exact Sciences competes through innovation speed, targeted oncology focus, and a growing body of clinical evidence that supports both guideline inclusion and payer reimbursement for its advanced tests.
-
Guardant Health:
Guardant Health is a leading innovator in liquid biopsy-based companion diagnostics devices, particularly in advanced solid tumors. Its blood-based assays allow non-invasive genomic profiling of tumors, which is highly valuable in guiding targeted treatments when tissue biopsies are difficult or risky. Many oncologists use Guardant’s tests to match patients to targeted therapies and to monitor treatment response over time.
For 2025, Guardant Health’s companion diagnostics-related revenue is estimated at USD 0.40 billion, resulting in a market share of approximately 5.10%. These numbers underscore the company’s strong competitive position among next-generation precision oncology players, with a focus on liquid biopsy rather than conventional tissue testing. The revenue base reflects both clinical adoption and partnerships with pharmaceutical manufacturers for use in clinical trials and therapy selection.
Guardant Health’s strategic edge resides in its proprietary liquid biopsy technology, extensive genomic database, and demonstrated sensitivity in detecting tumor mutations from blood. Its tests shorten time to treatment decisions and expand access to genomic profiling for patients who lack adequate tissue samples. Compared with traditional diagnostics firms, Guardant competes by offering minimally invasive, scalable solutions that align with evolving clinical guidelines and payer interest in value-based oncology care.
-
Foundation Medicine:
Foundation Medicine is a key specialist in comprehensive genomic profiling and companion diagnostics devices, especially for oncology. Its broad-panel NGS tests analyze hundreds of genes to identify actionable mutations and biomarkers, supporting the selection of targeted therapies, immunotherapies, and clinical trial options. The company’s reports are deeply integrated into oncology practice and tumor boards across many leading cancer centers.
In 2025, Foundation Medicine’s companion diagnostics revenue is estimated at USD 0.45 billion, corresponding to a market share of about 5.70%. These figures demonstrate a strong position in the high-complexity segment of the market, where comprehensive genomic profiling is increasingly preferred over single-gene assays. The scale of revenue indicates robust demand for broad-panel testing, especially in advanced or metastatic cancer cases.
Foundation Medicine differentiates itself through its extensive clinical evidence, high-quality bioinformatics, and strong collaborations with pharmaceutical manufacturers and academic institutions. Its tests are often referenced in therapy labels and clinical guidelines, which reinforces their role as de facto companion diagnostics for multiple agents. Compared with more generalized diagnostics providers, Foundation Medicine competes on depth of genomic coverage, interpretive reporting, and its close alignment with cutting-edge oncology research and drug development.
-
Invitae Corporation:
Invitae Corporation is an important genetics-focused participant in the companion diagnostics devices market, with a portfolio centered on hereditary cancer, cardiology, neurology, and rare disease testing. Its hereditary cancer panels support risk stratification and therapeutic decisions, including prophylactic interventions and selection of targeted therapies in patients with germline mutations. The company’s mission to broaden access to genetic testing dovetails with the expanding use of germline data in precision medicine.
For 2025, Invitae’s revenue associated with companion diagnostics is estimated at USD 0.28 billion, delivering a market share of around 3.50%. These values point to a meaningful role in germline-driven companion diagnostics, even as the company navigates a competitive and evolving reimbursement environment. The revenue scale shows that Invitae is a notable but not dominant player, with strong potential for growth as guidelines increasingly incorporate germline testing for therapy selection.
Invitae’s competitive advantages include broad test menus, relatively accessible pricing models, and integrated digital platforms that support ordering, reporting, and family testing. Its focus on clinician and patient education helps drive adoption in community settings, not just tertiary care centers. Compared with larger diversified diagnostics firms, Invitae competes through specialization in genetics, strong patient-centric services, and the ability to quickly expand panels to include newly validated genes with relevance to companion diagnostics.
-
Hologic:
Hologic contributes to the companion diagnostics devices market primarily through its strengths in women’s health, molecular diagnostics, and cytology. The company’s platforms, widely used for HPV, sexually transmitted infections, and cervical cancer screening, provide a base for expanding into therapy-linked biomarkers in gynecologic oncology and breast cancer. Its focus on women’s health positions it well to develop companion tests tailored to female-specific tumor types.
In 2025, Hologic’s revenue from companion diagnostics devices is estimated at USD 0.29 billion, equating to a market share of about 3.70%. This reflects a targeted but growing presence, leveraging its strong installed base in women’s health diagnostics. The revenue profile indicates that while companion diagnostics are not yet its largest segment, they represent a strategic growth avenue aligned with expanding targeted therapies in breast and gynecologic cancers.
Hologic’s strategic differentiation arises from its deep domain expertise in women’s health, strong relationships with obstetrics-gynecology and breast health clinics, and reliable automated platforms. By integrating companion diagnostics into existing screening and diagnostic pathways, Hologic can help clinicians move seamlessly from detection to personalized treatment selection. Compared with generalist diagnostics firms, Hologic’s focused clinical franchise and highly trusted brand in women’s health provide a distinct competitive edge as companion diagnostics evolve in this therapeutic area.
Key Companies Covered
Roche Diagnostics
Agilent Technologies
Thermo Fisher Scientific
Abbott Laboratories
Qiagen
Illumina
Siemens Healthineers
Danaher Corporation
Myriad Genetics
BioMerieux
Exact Sciences
Guardant Health
Foundation Medicine
Invitae Corporation
Hologic
Market By Application
The Global Companion Diagnostics Devices Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Oncology:
In oncology, the core business objective of companion diagnostics devices is to match cancer patients to targeted therapies and immunotherapies that deliver superior response rates and survival outcomes. These devices hold the largest market share among applications because most approved targeted oncology drugs require a validated biomarker assay as a prerequisite for reimbursement and use. Health systems adopt oncology-focused companion diagnostics because they can increase objective response rates by an estimated 20.00% to 50.00% compared with empiric chemotherapy, while reducing exposure to ineffective high-cost agents.
The unique operational outcome in oncology is the ability to stratify patients into molecularly defined subgroups, which can cut trial-and-error treatment cycles and shorten time to optimal regimen selection by several weeks. Hospitals and cancer centers report substantial drug budget optimization, with targeted use of high-cost biologics and kinase inhibitors reducing wasteful spending on non-responders by a significant portion of overall oncology pharmacy expenditures. Growth is propelled by rapid expansion of biomarker-driven indications, regulatory requirements that link drug labels to companion tests, and the rise of national precision oncology programs that embed biomarker testing into standardized cancer care pathways.
-
Neurology:
In neurology, the primary business objective of companion diagnostics devices is to identify patients with specific molecular or protein signatures that predict response to disease-modifying therapies, particularly in disorders such as Alzheimer’s disease and certain epilepsies. Although still emerging compared with oncology, neurology applications are gaining strategic importance as new therapeutics targeting amyloid, tau, and genetic epilepsies enter the market. Providers adopt these tools to reduce diagnostic uncertainty and avoid years of ineffective treatment, thereby decreasing the time to accurate therapeutic alignment by an estimated 30.00% to 40.00%.
The distinctive operational outcome in neurology is the ability to combine biomarker evidence from cerebrospinal fluid, blood, or imaging-derived markers with clinical assessments to refine patient selection for high-cost biologics and gene-targeted interventions. This approach can improve trial enrollment efficiency and reduce screen failure rates for neurology studies by a substantial margin, directly impacting development timelines and costs. Growth is driven by technological advances in blood-based biomarkers, regulatory encouragement for early and accurate diagnosis of neurodegenerative diseases, and rising payer scrutiny that requires objective evidence before approving expensive long-term neurological treatments.
-
Cardiology:
In cardiology, companion diagnostics devices focus on identifying patients who will benefit most from specific antithrombotic agents, lipid-lowering drugs, or therapies targeting inherited cardiomyopathies and channelopathies. The business objective is to optimize cardiovascular risk reduction while minimizing adverse events such as bleeding or arrhythmias. Hospitals and cardiology practices adopt these diagnostics to refine therapy choices, which can reduce major adverse cardiovascular events by a measurable percentage and decrease hospital readmissions associated with suboptimal drug selection.
The key operational outcome in cardiology is personalized risk stratification, where genetic and biomarker-based information guides dosing and choice of agents, often shortening the time needed to reach guideline-recommended targets such as LDL cholesterol or blood pressure control. By reducing adverse drug reactions and unnecessary treatment escalation, these tools can lower cardiovascular care costs per patient episode by a meaningful amount, especially in high-risk populations. Growth is fueled by the increasing integration of pharmacogenomics into cardiovascular care, regulatory support for labeling that references genetic markers, and employer and payer initiatives aimed at reducing the long-term economic burden of cardiovascular disease.
-
Infectious Diseases:
In infectious diseases, the core business objective of companion diagnostics devices is to rapidly identify pathogen-specific or resistance-associated markers that guide targeted antimicrobial or antiviral therapy. This application is essential in settings such as HIV, hepatitis, and certain multidrug-resistant bacterial infections where resistance profiles dramatically influence treatment choice and outcomes. Healthcare providers adopt these solutions because they can reduce time to effective therapy by 24.00 to 72.00 hours compared with empirical treatment, directly lowering morbidity and mortality risks.
The unique operational outcome in infectious diseases is optimized antimicrobial stewardship, where precise molecular information allows narrow-spectrum, high-efficacy drug selection and minimizes unnecessary broad-spectrum usage. Institutions implementing such diagnostics frequently report reductions in inappropriate antimicrobial use by an estimated 20.00% to 40.00%, with parallel decreases in length of stay and isolation days. Growth is catalyzed by global antimicrobial resistance initiatives, reimbursement incentives for rapid diagnostics, and regulatory pressure on hospitals to demonstrate improved stewardship metrics and infection-control performance.
-
Autoimmune Disorders:
For autoimmune disorders, companion diagnostics devices aim to identify biomarker-defined subgroups that respond better to specific biologics or small-molecule immunomodulators. Diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and systemic lupus erythematosus are increasingly managed with high-cost targeted therapies where response rates can vary widely between patients. Providers adopt these diagnostics to avoid prolonged cycles of ineffective biologics, which can otherwise extend over 6.00 to 12.00 months before a switch in therapy is considered.
The main operational outcome is improved treatment sequencing and faster achievement of disease control benchmarks such as remission or low disease activity scores. By guiding therapy choice earlier in the care pathway, companion diagnostics can reduce the number of failed biologic lines and associated drug wastage by a significant portion, improving overall cost-effectiveness in specialty pharmacy budgets. Market growth is supported by payer pressure to justify biologic use with objective evidence, increasing availability of validated autoimmune biomarkers, and evolving treatment guidelines that reference molecular or serologic markers in therapy selection algorithms.
-
Metabolic Disorders:
In metabolic disorders, particularly type 2 diabetes, familial hypercholesterolemia, and certain rare inborn errors of metabolism, companion diagnostics devices are used to stratify patients based on genetic and biochemical profiles that predict response to targeted agents. The business objective is to improve long-term metabolic control and prevent costly complications such as cardiovascular events, renal failure, or neuropathy. Health systems adopt these tools to support precision dosing and therapy selection, which can improve achievement of glycemic or lipid targets by a meaningful percentage compared with standard treatment escalation pathways.
The distinctive operational outcome is the alignment of drug mechanisms with individual metabolic pathways, allowing more rapid and sustained control of biomarkers such as HbA1c, LDL cholesterol, or specific metabolites. This alignment can shorten the trial-and-error period for dose optimization from several months to a much shorter window, reducing clinic visits and laboratory monitoring requirements. Growth is driven by the proliferation of novel metabolic therapies, broader screening for genetic lipid disorders, and payer initiatives that link reimbursement to documented improvements in metabolic performance indicators.
-
Hematology:
In hematology, companion diagnostics devices primarily address hematologic malignancies such as leukemias, lymphomas, and myeloma, as well as certain inherited bleeding and clotting disorders. The business objective is to segment patients according to cytogenetic, molecular, or minimal residual disease markers that guide use of targeted therapies, monoclonal antibodies, and cell-based treatments. Adoption is high in specialized hematology centers because biomarker-defined risk stratification can improve complete response rates and progression-free survival by substantial margins compared with non-stratified approaches.
The operational outcome in hematology is highly granular disease monitoring, where quantitative assays track residual disease levels and inform decisions about treatment intensification, transplantation, or therapy discontinuation. Implementing such diagnostics can reduce relapse-related hospitalizations and emergency interventions by a significant portion, improving both clinical outcomes and resource utilization. Growth is fueled by the rapid expansion of targeted hematology pipelines, regulatory approvals that specify biomarker-driven treatment pathways, and the integration of molecular minimal residual disease testing into clinical trial endpoints and routine practice.
-
Respiratory Diseases:
For respiratory diseases, companion diagnostics devices focus on segmenting patients with conditions such as non-small cell lung cancer, severe asthma, and chronic obstructive pulmonary disease based on molecular or inflammatory biomarkers. The key business objective is to direct high-cost biologics and targeted agents to patients most likely to benefit, while avoiding unnecessary treatment in low-response groups. Pulmonology clinics and integrated delivery networks adopt these diagnostics to improve symptom control and reduce acute exacerbations, which can lower emergency visits and hospital admissions by a notable percentage.
The unique operational outcome is precision management of airway inflammation and tumor biology, where biomarkers such as eosinophil counts, IgE levels, or specific gene mutations directly inform therapy choice. By tailoring treatment intensity to biomarker status, providers can optimize biologic dosing schedules and reduce wasted drug expenditures, improving return on investment for respiratory therapeutics within a relatively short payback period. Growth is driven by the increasing availability of biomarker-linked asthma and lung cancer therapies, updated clinical guidelines that emphasize biomarker testing, and payer policies that require documented biomarker positivity before authorizing expensive respiratory biologics and targeted agents.
Key Applications Covered
Oncology
Neurology
Cardiology
Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Hematology
Respiratory Diseases
Mergers and Acquisitions
The Companion Diagnostics Devices Market has experienced a surge in deal flow, as pharmaceutical manufacturers, platform diagnostics players, and AI-enabled genomics firms pursue targeted acquisitions. Over the last twenty‑four months, transactions have concentrated around oncology assay portfolios, biomarker discovery platforms, and regulated IVD manufacturing capacity. Consolidation is driven by the need to de‑risk drug launches, shorten time‑to‑market for companion tests, and secure access to high‑value patient stratification data. Strategic buyers are paying premiums to lock in clinically validated companion diagnostics linked to blockbuster therapeutics.
Major M&A Transactions
Roche – Foundation Medicine
Expands oncology sequencing companion diagnostics and strengthens biomarker-driven clinical trial enrollment.
Thermo Fisher Scientific – Invivoscribe CDx Assets
Adds hematology companion tests and global regulatory approvals to support pharma partnerships.
Qiagen – NeuMoDx Equity Buyout
Integrates fully automated PCR platforms for high-throughput companion diagnostic assay deployment.
Danaher – Aldevron Genomic Tools
Enhances nucleic acid capabilities for next-generation gene therapy companion diagnostics development.
Agilent Technologies – Resolution Bioscience
Acquires liquid biopsy technology to expand blood-based companion diagnostics in solid tumors.
Illumina – GRAIL Stake Increase
Strengthens multi-cancer early detection platform as a companion diagnostic for targeted therapies.
bioMérieux – Specific Diagnostics
Adds rapid phenotypic testing relevant for antibiotic stewardship companion diagnostics solutions.
Siemens Healthineers – Varian Software Assets
Integrates oncology decision-support software to pair imaging with therapy-linked companion diagnostics.
Recent M&A is accelerating market concentration in companion diagnostics devices, as diversified IVD leaders assemble end‑to‑end drug–diagnostic ecosystems. By integrating NGS platforms, PCR systems, and digital pathology under single ownership, acquirers are improving bargaining power with biopharma sponsors and payers. This trend favors companies that can bundle assay development, clinical validation, and global regulatory submissions, reducing execution risk for targeted oncology and immunology launches.
Valuation multiples have expanded alongside expectations for the market to grow from 7.90 Billion in 2025 to 17.90 Billion in 2032 at a 12.30% CAGR. Assets with FDA‑approved or EMA‑approved companion tests tied to high‑revenue therapies command the highest premiums, especially when supported by real‑world evidence repositories. Investors are rewarding platforms that generate recurring kit, reagent, and software revenues rather than project‑based service models, pushing deal structures toward earn‑outs linked to test adoption.
Strategically, acquirers are prioritizing portfolios that offer multi‑omics capabilities, including genomics, transcriptomics, and circulating tumor DNA analysis. This broad assay coverage allows them to co‑develop companion diagnostics across multiple drug programs with shared infrastructure, improving return on invested capital. Smaller innovators are increasingly positioning themselves as acquisition targets by focusing on niche biomarkers and rare disease indications where large buyers lack in‑house expertise.
Regionally, North America and Western Europe dominate deal volume, driven by dense oncology pipelines and established reimbursement pathways for companion diagnostics devices. Asia‑Pacific is emerging as a critical M&A arena, particularly in China and South Korea, where local players offer cost‑competitive NGS and PCR systems combined with large oncology patient cohorts.
Technology themes shaping the mergers and acquisitions outlook for Companion Diagnostics Devices Market include liquid biopsy, AI‑based image analysis for digital pathology, and cloud‑native bioinformatics pipelines. Buyers are targeting platforms that seamlessly integrate with electronic health records and clinical decision support tools, enabling scalable deployment of companion tests in community oncology settings and improving real‑world data capture.
Competitive LandscapeRecent Strategic Developments
In July 2023, Roche Diagnostics and Pfizer entered a strategic collaboration to co-develop companion diagnostics for select oncology assets, a partnership-type development that strengthened Roche’s installed base in next‑generation sequencing (NGS) platforms. This move intensified competition in oncology companion diagnostics by coupling a leading pharmaceutical pipeline with an established in‑vitro diagnostics player, raising the bar for smaller assay developers that lack integrated drug–diagnostic commercialization capabilities.
In March 2023, Thermo Fisher Scientific expanded its companion diagnostics portfolio through an agreement with Moderna to develop assays linked to mRNA-based oncology therapeutics, an expansion-type initiative that broadened Thermo Fisher’s biomarker menu on its NGS and PCR systems. This development accelerated the shift toward multiplex assays, pressuring competitors to enhance biomarker discovery pipelines and shorten validation timelines for clinical laboratories.
In January 2024, Qiagen completed the strategic acquisition of Verogen, an acquisition-type transaction focused on NGS chemistry and bioinformatics. By integrating Verogen’s sequencing technologies, Qiagen improved its end-to-end companion diagnostics offering, increasing competitive pressure on mid-sized diagnostic firms and intensifying differentiation around workflow automation, turnaround time, and regulatory-ready assay development.
SWOT Analysis
-
Strengths:
The global companion diagnostics devices market benefits from strong alignment with precision oncology and targeted therapy pipelines, which structurally ties device demand to high-value biologics and small-molecule launches. Robust regulatory frameworks for in vitro diagnostics, including clear pathways for co-development and simultaneous drug–diagnostic approval, support predictable commercialization timelines and enable premium pricing for FDA- or CE-marked companion assays. Established leaders in immunohistochemistry, polymerase chain reaction, and next-generation sequencing platforms leverage large analyzer installed bases, integrated reagent ecosystems, and long-term service contracts, creating high switching costs for hospital laboratories and reference centers. The market’s ability to generate actionable biomarker data, reduce adverse events, and improve response rates strengthens health technology assessment outcomes, supporting reimbursement decisions from payers focused on value-based care and driving recurring revenue from test utilization.
-
Weaknesses:
Despite strong clinical relevance, companion diagnostics devices face limited adoption outside top-tier cancer centers because of high capital expenditure for NGS instruments, complex validation workflows, and acute shortages of trained molecular pathologists and bioinformaticians. Many assays are tightly linked to single-drug indications, creating fragmented test menus and operational inefficiencies for laboratories that must manage multiple low-volume, branded kits across platforms. Lengthy codevelopment cycles with pharmaceutical sponsors expose diagnostic companies to pipeline risk, where late-stage drug failures can strand invested R&D and reduce portfolio utilization. Reimbursement remains inconsistent across geographies, with under-coding, low tariffs for biomarker testing, and payer skepticism about broad-panel assays constraining test volumes in community settings and emerging markets, which limits scale-up potential and slows return on investment on new analyzers and assay launches.
-
Opportunities:
The companion diagnostics devices market has substantial expansion potential as pharmaceutical pipelines increasingly prioritize biomarker-driven therapies in oncology, immunology, and rare diseases, creating demand for multi-analyte panels and pan-tumor assays. Rising investment in liquid biopsy technologies and circulating tumor DNA-based monitoring offers device manufacturers an opportunity to migrate from tissue-only to minimally invasive, longitudinal testing models that can generate recurring revenue per patient over the treatment journey. Geographic expansion into Asia-Pacific, Latin America, and the Middle East, where oncology incidence is rising and health systems are upgrading molecular diagnostics infrastructure, can unlock new installed bases and higher test throughput. Integration of artificial intelligence-enabled image analysis and bioinformatics into companion diagnostics workflows can differentiate vendors through faster turnaround times, improved variant interpretation, and streamlined reporting for clinicians, increasing the clinical utility and perceived value of advanced assay menus.
-
Threats:
The companion diagnostics devices market faces regulatory uncertainty from evolving requirements for in vitro diagnostic regulation, which may tighten evidence standards, extend approval timelines, and increase compliance costs for both platforms and individual assays. Competitive pressure from centralized mega-labs and integrated diagnostic-service providers offering lab-developed tests can erode market share for kit-based, branded companion diagnostics, particularly where hospital systems prioritize cost over branded alignment with specific therapies. Rapid innovation in sequencing technologies and digital pathology creates risk of technological obsolescence for existing analyzers, forcing vendors to invest heavily in continuous platform upgrades and migrations. Pricing pressure from payers, coupled with value-based contracting for drugs, may push pharmaceutical partners to renegotiate revenue-sharing models and narrow the number of officially endorsed companion diagnostics per indication, concentrating bargaining power among a few leading device manufacturers and disadvantaging smaller players.
Future Outlook and Predictions
The global companion diagnostics devices market is expected to trend toward sustained double-digit expansion over the next decade, anchored by strong precision oncology pipelines and broader adoption beyond tertiary cancer centers. Using ReportMines data as a baseline, the market is forecast to grow from USD 7.90 billion in 2025 to USD 8.90 billion in 2026 and reach USD 17.90 billion by 2032, reflecting a compound annual growth rate of 12.30 percent. This trajectory indicates that companion diagnostics will increasingly be embedded as a prerequisite for access to targeted therapies, making test availability and turnaround time critical determinants of drug uptake and formulary positioning.
Technological evolution will be dominated by next-generation sequencing consolidation and the rise of multi-biomarker panels. Over the next 5–10 years, oncology portfolios are expected to move from single-mutation assays toward comprehensive genomic profiling and pan-tumor signatures, driven by the need to capture complex resistance mechanisms and rare variants. Device vendors that integrate sequencing chemistries with automated sample preparation, cloud-based bioinformatics, and structured reporting will be positioned to become end-to-end precision medicine platforms rather than commodity instrument suppliers.
Liquid biopsy and minimal residual disease monitoring are likely to become key growth vectors within the companion diagnostics devices landscape. As circulating tumor DNA assays gain clinical validation for predicting relapse, guiding therapy switches, and monitoring response, hospitals and reference laboratories will invest in platforms capable of both tissue and blood-based workflows. This shift will favor instruments with high analytical sensitivity, robust error correction, and flexible menu expansion, while creating recurring revenue opportunities through longitudinal testing over the patient treatment journey.
Regulatory and reimbursement dynamics will increasingly shape which technologies and vendors capture outsized value. Regulators are expected to push further toward co-approval models and companion diagnostics labeling requirements in oncology and selected immunology indications, reinforcing the link between specific assays and drug brands. At the same time, payers will demand stronger real-world evidence demonstrating that biomarker-guided treatment improves outcomes and reduces ineffective drug spend, incentivizing manufacturers to embed health economic endpoints and outcomes data collection into post-launch strategies.
Competitive dynamics will likely concentrate around a few global players that can coordinate pharmaceutical partnerships, global regulatory submissions, and service-intensive deployments across major regions. However, regional manufacturers and specialized laboratories will exploit niches in local regulatory environments, rare disease panels, and cost-sensitive segments, particularly in Asia-Pacific and Latin America. Over the next decade, successful market participants will be those that pair technological innovation with scalable commercialization models, joint drug–diagnostic development, and integrated informatics that simplify clinical decision-making for busy oncology practices.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Companion Diagnostics Devices Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Companion Diagnostics Devices by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Companion Diagnostics Devices by Country/Region, 2017,2025 & 2032
- 2.2 Companion Diagnostics Devices Segment by Type
- Polymerase Chain Reaction Based Companion Diagnostics Devices
- Next Generation Sequencing Based Companion Diagnostics Devices
- Immunohistochemistry Based Companion Diagnostics Devices
- In Situ Hybridization Based Companion Diagnostics Devices
- Liquid Biopsy Based Companion Diagnostics Devices
- Mass Spectrometry Based Companion Diagnostics Devices
- 2.3 Companion Diagnostics Devices Sales by Type
- 2.3.1 Global Companion Diagnostics Devices Sales Market Share by Type (2017-2025)
- 2.3.2 Global Companion Diagnostics Devices Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Companion Diagnostics Devices Sale Price by Type (2017-2025)
- 2.4 Companion Diagnostics Devices Segment by Application
- Oncology
- Neurology
- Cardiology
- Infectious Diseases
- Autoimmune Disorders
- Metabolic Disorders
- Hematology
- Respiratory Diseases
- 2.5 Companion Diagnostics Devices Sales by Application
- 2.5.1 Global Companion Diagnostics Devices Sale Market Share by Application (2020-2025)
- 2.5.2 Global Companion Diagnostics Devices Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Companion Diagnostics Devices Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report